亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

作者
Simon Harrison,Caroline Hasselbalch Riley,Hira S. Mian,Andrew Spencer,Noa Lavi,Laura Paris,Jana Mihalyova,Rakesh Popat,Monika Szarejko,Sebastian Grosicki,Kihyun Kim,Irwindeep Sandhu,Sammy Chebon,Tulika Tyagi,Paresh Sewpaul,Leanne Richardson,Kerstin Trunzer,Ameet Mishra,Suzanne Trudel
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 252-252 被引量:10
标识
DOI:10.1182/blood-2025-252
摘要

Abstract Background Fc receptor-homolog 5 (FcRH5) is a type I membrane protein that is ubiquitously expressed on multiple myeloma cells. Cevostamab, a FcRH5xCD3 T-cell-engaging bispecific antibody, has shown encouraging activity and manageable safety as monotherapy in late-line RRMM (Richter et al. ASH 2024). Combining cevostamab with anti-myeloma agents that augment T-cell activity could enhance efficacy. Pomalidomide (Pom) is an immunomodulatory drug (IMiD) that exhibits T-cell co-stimulatory effects and is clinically active when given alone or with dexamethasone (dex) in RRMM (San Miguel et al. 2013). In the Arm B randomized dose-expansion stage of the Phase Ib CAMMA 1 study (NCT03275103), cevostamab plus Pom-dex induced deep and durable responses and had manageable safety in patients (pts) with RRMM (Mian et al. IMS 2025). We report exploratory biomarker analyses from Arm B that aimed to characterize tumor kinetics, MRD, and immune correlates of response. Methods In the Arm B randomized dose-expansion cohorts, eligible pts had RRMM and had received ≥1 prior IMiD and ≥1 prior proteasome inhibitor as part of ≥1 prior line. Pts were randomized (1:1) to receive 70mg (low-dose [LD]) or 105mg (high-dose [HD]) cevostamab given Q2W in Cycles (C) 1–6 (28-day cycle) and Q4W in C7+, after a pre-phase with double or triple step-up dosing. Pom (2mg Day [D] 1–21) and dex (20mg D1, 8, 15, and 22) were given from C1+. Treatment continued until disease progression or unacceptable toxicity. Soluble B-cell maturation antigen (sBCMA), a surrogate biomarker for tumor burden, and cytokines were measured in plasma using LC/MS and multiplex ELISA assays on ELLA platform. MRD was assessed using Adaptive clonoSEQ® (sensitivity: 10−4 to 10−6). Immunophenotyping was carried out using multiparameter conventional and spectral flow. Given the negative impact of prior exposure to BCMA-targeted agents on outcomes (Richter et al. ASH 2024), analyses were conducted in BCMA-naïve pts only. Results As of June 11, 2025, 64 pts were randomized and treated in the Arm B dose-expansion cohorts (LD, n=32; HD, n=32). Of these, 29 pts in the LD group and 25 pts in the HD group were BCMA naïve (median age: 65 years in both groups [range: LD, 40–76; HD, 48–80]; male: 48.3% and 56.0%, respectively). Among these pts, median number of prior lines of therapy was 2 [range: 1–6] in both groups and the majority were refractory to their last line of therapy (LD, 72.4%; HD, 68.0%). At data cut-off, median time on study in BCMA-naïve pts was 10.4 months (range: 6.3–15.5) in the LD group and 8.3 months (range: 3.3–15.7) in the HD group. The objective response rate (ORR) and very good partial response (VGPR) or better rate were 86.2% and 72.4% in the LD group and 88.0% and 76.0% in the HD group. At cut-off, 84.0% of BCMA-naïve responders in the LD group and 86.4% in the HD group remained in response, with deepening responses observed over time. Baseline sBCMA levels and effector-to-target ratios in BCMA-naïve pts were comparable in the LD and HD groups. CD8⁺ T-cell subset distribution and activation markers also showed no difference between groups, while heatmap clustering confirmed immunological comparability for T-cell fitness. In BCMA-naïve pts, cevostamab plus pom-dex induced rapid, deep, and durable declines in sBCMA levels. Median sBCMA decreases were 54.9% by C1D1 pre-infusion (after the first target dose in the cevostamab pre-phase), 83.0% by C1D15 and 90.9% by C2D1 pre-infusion. Notably, no significant difference in sBCMA kinetics or the depth of sBCMA depletion was observed between the LD and HD groups. In the BCMA-naïve group, 25 pts achieved a complete response or better (CR+) and 20 pts were evaluable for MRD assessment. Of these, 14 pts achieved best MRD negativity at the 10−6 threshold level, 3 pts at the 10−5 threshold and 1 patient at the 10−4 threshold. Two pts had calibration failure at screening, and 5 pt samples were not reconciled at cut-off. There was no significant difference for CR+MRD-negativity rate between the LD (9/13, 69.2%) and HD (8/12, 66.7%) groups at the 10−5 threshold in CR+ pts.Conclusions Cevostamab plus Pom-dex induces high ORR and VGPR or better rates, and durable remissions, in BCMA-naïve pts with RRMM. Combination treatment is also associated with deep and durable declines in sBCMA levels and high rates of CR+MRD-negativity. Updated biomarker data will be presented, including baseline immune fitness and correlation with MRD negativity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被交大·勒布朗采纳,获得30
11秒前
26秒前
成就马里奥完成签到,获得积分10
26秒前
28秒前
31秒前
纯情的阁发布了新的文献求助10
34秒前
42秒前
深情的从丹完成签到,获得积分10
46秒前
50秒前
阿丕啊呸完成签到,获得积分10
55秒前
58秒前
59秒前
null的应助被伊比利亚的微风采纳,获得10
1分钟前
认真的笑卉完成签到,获得积分10
1分钟前
1分钟前
aba发布了新的文献求助10
1分钟前
hamburger完成签到,获得积分10
1分钟前
null的应助被等待若魔采纳,获得10
1分钟前
陶醉成协完成签到,获得积分10
1分钟前
haralee完成签到 ,获得积分10
1分钟前
1分钟前
乐正元正完成签到,获得积分10
1分钟前
时尚的蜜蜂完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
2分钟前
2分钟前
Logan1001发布了新的文献求助10
2分钟前
2分钟前
2分钟前
bkagyin的应助被Logan1001采纳,获得10
2分钟前
hyman发布了新的文献求助10
2分钟前
2分钟前
2分钟前
生动琦完成签到,获得积分10
2分钟前
彩色的可冥完成签到,获得积分10
2分钟前
Logan1001完成签到,获得积分20
2分钟前
2分钟前
从容煜城完成签到,获得积分10
2分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354